Changing Patterns of Causative Pathogens over Time and Efficacy of Empirical Antibiotic Therapies in Acute Cholangitis with Bacteremia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To select appropriate empirical antibiotics, updates on the changes in pathogens are essential. We aimed to investigate the changes in pathogens and their antibiotic susceptibility in acute cholangitis (AC) with bacteremia over a period of 15 years. Furthermore, the efficacy of empirical antibiotic therapies and the risk factors predicting antibiotic-resistant pathogens (ARPs) were analyzed. Methods: A total of 568 patients with AC and bacteremia who were admitted to Daegu Catholic University Medical Center from January 2006 to December 2020 were included. Their medical records were retrospectively reviewed. In addition, the data were grouped and analyzed at 3-year intervals under the criteria of Tokyo Guideline 2018. Results: During the study period, 596 pathogens were isolated from blood cultures of 568 patients. The three most common pathogens were Escherichia coli (50.5%), Klebsiella species (24.5%), and Enterococcus species (8.1%). The proportion of vancomycin-resistant Enterococci (VRE) has increased since the mid-2010 (0.0% to 4.3%, p=0.007). There was emergence of carbapenem-resistant Enterobacteriaceae (CRE) in 2018 to 2020, albeit not statistically significant (1.3%, p=0.096). Risk factors predicting ARP were healthcare-associated infection, history of previous biliary intervention, and the severity of AC. For patients with these aforementioned risk factors, imipenem was the most effective antibiotic and piperacillin-tazobactam was also effective but to a lesser degree (susceptibility rates of 92.1% and 75.0%, respectively). Conclusions: The proportion of VRE has increased and CRE has emerged in AC. In addition, healthcare-associated infection, history of previous biliary intervention, and the severity of AC were independent risk factors predicting ARP. For patients with these risk factors, the administration of imipenem or piperacillin-tazobactam should be considered.
Abstract
Background/Aims: To select appropriate empirical antibiotics, updates on the changes in pathogens are essential. We aimed to investigate the changes in pathogens and their antibiotic susceptibility in acute cholangitis (AC) with bacteremia over a period of 15 years. Furthermore, the efficacy of empirical antibiotic therapies and the risk factors predicting antibiotic-resistant pathogens (ARPs) were analyzed. Methods: A total of 568 patients with AC and bacteremia who were admitted to Daegu Catholic University Medical Center from January 2006 to December 2020 were included. Their medical records were retrospectively reviewed. In addition, the data were grouped and analyzed at 3-year intervals under the criteria of Tokyo Guideline 2018. Results: During the study period, 596 pathogens were isolated from blood cultures of 568 patients. The three most common pathogens were Escherichia coli (50.5%), Klebsiella species (24.5%), and Enterococcus species (8.1%). The proportion of vancomycin-resistant Enterococci (VRE) has increased since the mid-2010 (0.0% to 4.3%, p=0.007). There was emergence of carbapenem-resistant Enterobacteriaceae (CRE) in 2018 to 2020, albeit not statistically significant (1.3%, p=0.096). Risk factors predicting ARP were healthcare-associated infection, history of previous biliary intervention, and the severity of AC. For patients with these aforementioned risk factors, imipenem was the most effective antibiotic and piperacillin-tazobactam was also effective but to a lesser degree (susceptibility rates of 92.1% and 75.0%, respectively). Conclusions: The proportion of VRE has increased and CRE has emerged in AC. In addition, healthcare-associated infection, history of previous biliary intervention, and the severity of AC were independent risk factors predicting ARP. For patients with these risk factors, the administration of imipenem or piperacillin-tazobactam should be considered.
참고문헌 (32)
- Miura F, "Tokyo Guidelines 2018 : initial management of acute biliary infection and flowchart for acute cholangitis", J Hepatobiliary Pancreat Sci, 25, pp.31~40 (2018)
- Ahmed M, "Acute cholangitis : an update", World J Gastrointest Pathophysiol, 9, pp.1~7 (2018)
- Gomi H, "Tokyo Guidelines 2018 : antimicrobial therapy for acute cholangitis and cholecystitis", J Hepatobiliary Pancreat Sci, 25, pp.3~16 (2018)
- Tagashira Y, "Impact of inadequate initial antimicrobial therapy on mortality in patients with bacteraemic cholangitis : a retrospective cohort study", Clin Microbiol Infect, 23, pp.740~747 (2017)
- Khashab MA, "Delayed and unsuccessful endoscopic retrograde cholangiopancreatography are associated with worse outcomes in patients with acute cholangitis", Clin Gastroenterol Hepatol, 10, pp.1157~1161 (2012)
- Lee F, "Delayed endoscopic retrograde cholangiopancreatography is associated with persistent organ failure in hospitalised patients with acute cholangitis", Aliment Pharmacol Ther, 42, pp.212~220 (2015)
- Vu TLH, "Factors influencing choices of empirical antibiotic treatment for bacterial infections in a scenario-based survey in Vietnam", JAC Antimicrob Resist, 2, pp.dlaa087~ (2020)
- Haggard E, "Minimum acceptable susceptibility of empirical antibiotic regimens for gram-negative bloodstream infections : a survey of clinical pharmacists", Infect Dis Clin Pract, 26, pp.283~287 (2018)
- 권정석, "Changes in Causative Pathogens of Acute Cholangitis and Their Antimicrobial Susceptibility over a Period of 6 Years", 대한소화기학회지, 63(5), pp.299~307 (2014), 대한소화기학회
- Sung YK, "The clinical epidemiology and outcomes of bacteremic biliary tract infections caused by antimicrobial-resistant pathogens", Am J Gastroenterol, 107, pp.473~483 (2012)
- Lee JK, "Updates in bacteriological epidemiology of community-acquired severe acute cholangitis and the effectiveness of metronidazole added routinely to the first-line antimicrobial regimen", J Infect Chemother, 19, pp.1029~1034 (2013)
- Kiriyama S, "Tokyo Guidelines 2018 : diagnostic criteria and severity grading of acute cholangitis(with videos)", J Hepatobiliary Pancreat Sci, 25, pp.17~30 (2018)
- Weinstein MP, "The clinical significance of positive blood cultures in the 1990s : a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults", Clin Infect Dis, 24, pp.584~602 (1997)
- Wilson SJ, "Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital", Am J Infect Control, 32, pp.342~344 (2004)
- Ohmagari N, "Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer", Cancer, 104, pp.205~212 (2005)
- Solomkin JS, "Diagnosis and management of complicated intra-abdominal infection in adults and children : guidelines by the Surgical Infection Society and the Infectious Diseases Society of America", Clin Infect Dis, 50, pp.133~164 (2010)
- Lavillegrand JR, "Acute cholangitis in intensive care units : clinical, biological, microbiological spectrum and risk factors for mortality : a multicenter study", Crit Care, 25, pp.49~ (2021)
- Kruis T, "Use of microbiological and patient data for choice of empirical antibiotic therapy in acute cholangitis", BMC Gastroenterol, 20, pp.65~ (2020)
- Karasawa Yuki, "Risk Factors for Acute Cholangitis Caused by Enterococcus faecalis and Enterococcus faecium", Gut and Liver, 15(4), pp.616~624 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Bezabih YM, "The global prevalence and trend of human intestinal carriage of ESBLproducing Escherichia coli in the community", J Antimicrob Chemother, 76, pp.22~29 (2021)
- Jang DK, "Increasing burden of biliary tract infection caused by extended-spectrum beta-lactamase-producing organisms in Korea : a nationwide population-based study", J Gastroenterol Hepatol, 35, pp.56~64 (2020)
- Lutgring JD, "Carbapenem-resistant Enterobacteriaceae : an emerging bacterial threat", Semin Diagn Pathol, 36, pp.182~186 (2019)
- Ben-David D, "Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections", Clin Microbiol Infect, 18, pp.54~60 (2012)
- Raza T, "Vancomycin resistant Enterococci : a brief review", J Pak Med Assoc, 68, pp.768~772 (2018)
- Lodise TP, "Clinical outcomes for patients with bacteremia caused by vancomycinresistant enterococcus in a level 1 trauma center", Clin Infect Dis, 34, pp.922~929 (2002)
- Tan M, "Analysis of patterns of bacteremia and 30-day mortality in patients with acute cholangitis over a 25-year period", Scand J Gastroenterol, 56, pp.578~584 (2021)
- Schneider J, "Mortality risk for acute cholangitis(MAC) : a risk prediction model for inhospital mortality in patients with acute cholangitis", BMC Gastroenterol, 16, pp.15~ (2016)
- Ventola CL, "The antibiotic resistance crisis : part 1 : causes and threats", P T, 40, pp.277~283 (2015)
- Reuken PA, "Risk factors for multidrug resistant pathogens and failure of empiric first-line therapy in acute cholangitis", PLoS One, 12, pp.e0169900~ (2017)
- Schneider J, "Risk factors for increased antimicrobial resistance : a retrospective analysis of 309 acute cholangitis episodes", J Antimicrob Chemother, 69, pp.519~525 (2014)
- 구자충, "Extended Spectrum-β-Lactamase or Carbapenemase Producing Bacteria Isolated from Patients with Acute Cholangitis", Clinical Endoscopy, 45(2), pp.155~160 (2012), 대한소화기내시경학회
- Harris PNA, "Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance : a randomized clinical trial", JAMA, 320, pp.984~994 (2018)